73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101.

MLA

Masuishi, T., et al. “73MO Sotorasib (Soto), Panitumumab (Pani), and FOLFIRI in First-Line (1L) KRAS G12C–mutated Metastatic Colorectal Cancer (MCRC): Regional Analysis of Safety and Efficacy from CodeBreaK 101.” Annals of Oncology, vol. 35, Dec. 2024, p. S1432. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.10.095.

APA

Masuishi, T., Yamaguchi, K., Rodriguez, J. C. R., Corral de la Fuente, E., Kuboki, Y., Cremolini, C., Ruiz, I. V., Fernandez, M. E. E., Strickler, J. H., Furqan, M., Bashir, B., Nduka, C., Hippenmeyer, J., Chan, E., Xia, C., & Siena, S. (2024). 73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101. Annals of Oncology, 35, S1432. https://doi.org/10.1016/j.annonc.2024.10.095

Chicago

Masuishi, T., K. Yamaguchi, J.C. Ruffinelli Rodriguez, E. Corral de la Fuente, Y. Kuboki, C. Cremolini, I. Victoria Ruiz, et al. 2024. “73MO Sotorasib (Soto), Panitumumab (Pani), and FOLFIRI in First-Line (1L) KRAS G12C–mutated Metastatic Colorectal Cancer (MCRC): Regional Analysis of Safety and Efficacy from CodeBreaK 101.” Annals of Oncology 35 (December): S1432. doi:10.1016/j.annonc.2024.10.095.